Professional Eyecare Optometrist Medicare: Medicare Enrolled Practice Location: 1511 M St, Ord, NE 68862 Phone: 308-729-3229 Fax: 308-728-5908 |
Dr. Brandon A. Blair, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1511 M St, Box 263, Ord, NE 68862 Phone: 308-728-3229 Fax: 308-728-5908 |
Unity Eye Centers Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1511 M St, Ord, NE 68862 Phone: 308-728-3229 |
Dr. Roger C Mccartney, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1511 M St, Ord, NE 68862 Phone: 308-728-3229 Fax: 308-728-5908 |
Dorsey Eyecare Pc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 314 S 14th St Ste 202, Ord, NE 68862 Phone: 308-728-7700 Fax: 308-728-7720 |
Dr. Mindy K Dorsey, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1511 M St, Ord, NE 68862 Phone: 308-728-3229 Fax: 308-728-5908 |
News Archive
A multicenter team of investigators, led by researchers from the Cedars-Sinai Department of Neurosurgery, the Cedars-Sinai Maxine Dunitz Neurosurgical Institute and Dana-Farber Cancer Institute in Boston, have found in a Phase II clinical trial that an immune system-boosting therapy slowed the recurrence of glioblastoma multiforme, or GBM, the most common and deadly malignant brain tumor.
Scientists studying the most common and aggressive type of brain tumor in adults have discovered a new way of analyzing diseased and healthy cells from the same patient.
Unravelling the mechanical properties of bone with micro-indentation testing has significance in both health and disease. At the University Medical Center Hamburg-Eppendorf, Dr. Björn Busse and his research group have advanced their micro-indentation testing technique using an Olympus industrial inspection digital light microscope, as an alternative to electron microscopy. The cutting edge research is described in a new application note from Olympus, available online.
ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that it has entered into a research and license option agreement regarding its ICT-69 antibody with Roche Group (SWX: ROG.VX; RO.S, OTCQX: RHHBY), one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics.
The significant reduction in vehicle journeys during the COVID-19 lockdown did not reduce the level of toxic fine particles in Scotland's air, according to experts at the University of Stirling.
› Verified 7 days ago